Clifford Swan Investment Counsel LLC Cuts Holdings in Bristol-Myers Squibb (NYSE:BMY)

Clifford Swan Investment Counsel LLC decreased its position in shares of Bristol-Myers Squibb (NYSE:BMYGet Rating) by 5.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 469,648 shares of the biopharmaceutical company’s stock after selling 25,275 shares during the period. Bristol-Myers Squibb makes up approximately 1.6% of Clifford Swan Investment Counsel LLC’s investment portfolio, making the stock its 11th biggest position. Clifford Swan Investment Counsel LLC’s holdings in Bristol-Myers Squibb were worth $33,387,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in BMY. Rise Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 16.0% in the second quarter. Rise Advisors LLC now owns 1,007 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 139 shares during the period. Cornerstone Wealth Group LLC lifted its stake in shares of Bristol-Myers Squibb by 4.9% in the second quarter. Cornerstone Wealth Group LLC now owns 2,982 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 140 shares during the period. Lincoln National Corp lifted its stake in shares of Bristol-Myers Squibb by 0.4% in the third quarter. Lincoln National Corp now owns 36,282 shares of the biopharmaceutical company’s stock valued at $2,579,000 after purchasing an additional 140 shares during the period. Global Retirement Partners LLC lifted its stake in shares of Bristol-Myers Squibb by 0.9% in the third quarter. Global Retirement Partners LLC now owns 15,822 shares of the biopharmaceutical company’s stock valued at $1,226,000 after purchasing an additional 143 shares during the period. Finally, Nicolet Bankshares Inc. raised its position in Bristol-Myers Squibb by 0.6% during the second quarter. Nicolet Bankshares Inc. now owns 23,174 shares of the biopharmaceutical company’s stock worth $1,784,000 after acquiring an additional 144 shares during the last quarter. Hedge funds and other institutional investors own 75.51% of the company’s stock.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Ann Powell sold 16,250 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $80.45, for a total transaction of $1,307,312.50. Following the completion of the sale, the executive vice president now directly owns 34,226 shares in the company, valued at $2,753,481.70. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Bristol-Myers Squibb news, EVP Rupert Vessey sold 45,910 shares of the business’s stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $78.88, for a total transaction of $3,621,380.80. Following the completion of the sale, the executive vice president now directly owns 57,079 shares in the company, valued at $4,502,391.52. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ann Powell sold 16,250 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $80.45, for a total transaction of $1,307,312.50. Following the sale, the executive vice president now owns 34,226 shares of the company’s stock, valued at $2,753,481.70. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Trading Up 0.1 %

Bristol-Myers Squibb stock traded up $0.09 during trading on Wednesday, reaching $72.43. The company had a trading volume of 781,493 shares, compared to its average volume of 8,047,362. Bristol-Myers Squibb has a 12-month low of $61.86 and a 12-month high of $81.43. The stock’s 50 day moving average price is $75.32 and its two-hundred day moving average price is $73.70. The firm has a market capitalization of $154.00 billion, a price-to-earnings ratio of 23.56, a PEG ratio of 1.63 and a beta of 0.44. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.31 and a current ratio of 1.42.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last released its earnings results on Tuesday, October 25th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.16. Bristol-Myers Squibb had a net margin of 14.29% and a return on equity of 50.30%. The firm had revenue of $11.22 billion during the quarter, compared to the consensus estimate of $11.18 billion. During the same period in the previous year, the firm earned $2.00 earnings per share. Bristol-Myers Squibb’s revenue was down 3.5% compared to the same quarter last year. As a group, equities analysts expect that Bristol-Myers Squibb will post 7.61 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Investors of record on Friday, January 6th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.15%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.54. The ex-dividend date is Thursday, January 5th. Bristol-Myers Squibb’s payout ratio is presently 74.27%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BMY shares. Cantor Fitzgerald started coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, January 17th. They set an “overweight” rating and a $95.00 target price for the company. Barclays cut their target price on shares of Bristol-Myers Squibb from $69.00 to $66.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 12th. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $70.00 to $78.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 3rd. Guggenheim cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Monday, October 10th. Finally, Morgan Stanley cut their target price on shares of Bristol-Myers Squibb from $61.00 to $60.00 and set an “underweight” rating for the company in a research report on Thursday, October 27th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.60.

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Featured Articles

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.